Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

The user's hair appears to have improved, looking thicker and healthier, especially around the temples, after using topical minoxidil, finasteride, dutasteride, and tretinoin. Most participants agree the last picture shows significant improvement, though one disagrees.

Microneedling can cause sneezing and eye tearing due to nerve stimulation, particularly near the temples and forehead. Some users find it lessens over time, while others prefer using finasteride and minoxidil for hair growth.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

Scalp microneedling with Exohealer significantly reduced hair shedding for the user. The treatment was done at Seoul Forena Clinic.

An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.

Finasteride may affect neurosteroids, impacting mood and sexual function, with varied user experiences. Some report side effects like depression and sexual dysfunction, while others find it effective for hair retention or prefer alternatives like Dutasteride or topical treatments.

The conclusion of this conversation is that the user "DuckSeasonCamelSeasn" found that consuming grapefruit juice prior to taking finasteride or dutasteride helped them become a responder to the medications and regain hair growth. However, there are warnings about potential risks and interactions with other medications, so caution should be exercised.

The user recovered from Post-Finasteride Syndrome (PFS) using a specific hormone protocol after trying finasteride and dutasteride. They now help others with PFS by reviewing blood work and offering personalized advice.

ET-02 is seen as promising for addressing hair loss and graying, but PP405 is more advanced in development and has better publicity. Some users plan to use both treatments alongside minoxidil and dutasteride.

PP405 targets hair follicle stem cells differently than exercise-induced lactate, suggesting exercise alone may not replicate its benefits. Minoxidil and finasteride are recommended alongside exercise for hair regrowth, with additional suggestions like spicy food and infrared exposure.

A 26-year-old male started minoxidil treatment for male-pattern baldness and saw significant regrowth in three months. He is considering finasteride but is hesitant due to potential side effects.

A 20-year-old male experienced early hair thinning due to male pattern baldness and successfully thickened his hair using oral finasteride and topical minoxidil. The conversation highlights the importance of early action and overcoming fear of medication side effects.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

Hair follicles are mostly dormant but can be reactivated with treatments like minoxidil, finasteride, and microneedling. A new drug, PP405, shows promise for hair regrowth but may not be available until 2027-2028.

A 22-year-old trans woman has been on 6mg estradiol enanthate for five months. She reports thicker and healthier hair but not much regrowth yet.

PP405 shows promise in reactivating dormant hair follicles, with early trials indicating some success, but it is not yet a proven treatment for hair loss. Users are advised to be cautious with unverified versions, and further research is needed to confirm its effectiveness compared to treatments like minoxidil and finasteride.

ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.

The user has been using oral finasteride and minoxidil for almost 8 months with minimal progress and continued hair shedding. Others suggest patience, as results may take up to two years, and advise against starting multiple treatments simultaneously.

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

Adipose-derived stem cells with ATP improved hair regrowth in male and female mice with androgenetic alopecia. The most effective treatments were low dose stem cells with ATP for males and medium dose stem cells with non-liposomal ATP for females.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

Exercise, especially leg workouts, combined with finasteride and minoxidil, may enhance hair regrowth. Cold exposure, like cold showers, might further boost results.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

PP405 aims to reactivate hair follicle stem cells to promote hair growth, but its effectiveness is debated. Some users are skeptical, citing past failures of similar treatments and questioning the company's claims.